{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:49:15Z","timestamp":1791910155754,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate nine-month outcomes after switching to faricimab in anti-VEGF-refractory retinal vein occlusion (RVO) under a modified treat-and-extend (T&amp;E) regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective real-world study, 34 eyes of 34 patients with macular edema (ME) secondary to RVO were switched to faricimab. Eligibility required persistent center-involving intraretinal fluid (IRF) across the three most recent treatment visits, central subfield thickness (CST)\u2009\u2265\u2009270\u00a0\u03bcm at switching, and \u2265\u20093 prior anti-VEGF injections with the three most recent intervals of 4\u20136 weeks and no ability to extend beyond six weeks. Treatment followed a modified T&amp;E regimen with a single loading dose. Best-corrected visual acuity (BCVA), CST, OCT biomarkers, and treatment intervals were evaluated through the fifth injection visit. Baseline-to-final comparisons were supplemented by longitudinal mixed-effects analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median BCVA improved from 0.2 to 0.1 logMAR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), and median CST decreased from 298 to 270\u00a0\u03bcm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). IRF decreased from 100% to 47% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and hyperreflective foci from 53% to 21% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Mean treatment intervals increased from 4.7\u2009\u00b1\u20090.9 to 9.5\u2009\u00b1\u20093.0 weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with extension possible in 94% of eyes. Both central and branch RVO subgroups showed significant interval extension. No intraocular inflammation or other serious ocular adverse events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to faricimab was associated with sustained anatomical improvement, modest functional benefit, and clinically meaningful interval extension. These findings support a response-guided modified T&amp;E switch strategy without a conventional loading phase in treatment-intensive RVO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>German Clinical Trials Register (DRKS): DRKS00036984.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07555-z","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:50:28Z","timestamp":1791863428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching to faricimab in anti-VEGF-refractory retinal vein occlusion: nine-month prospective real-world outcomes under a modified treat-and-extend regimen"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-091X","authenticated-orcid":false,"given":"Adnan","family":"Kilani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelmoudjib","family":"Ameur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Jochem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"7555_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, Wolf S, Loewenstein A (2019) Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica 242:123\u2013162. https:\/\/doi.org\/10.1159\/000502041","journal-title":"Ophthalmologica"},{"key":"7555_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","volume":"6","author":"TA Ciulla","year":"2022","unstructured":"Ciulla TA, Hussain RM, Taraborelli D, Pollack JS, Williams DF (2022) Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes. Ophthalmol Retina 6:796\u2013806. https:\/\/doi.org\/10.1016\/j.oret.2022.03.021","journal-title":"Ophthalmol Retina"},{"key":"7555_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease C (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313\u2013319e311. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017","journal-title":"Ophthalmology"},{"key":"7555_CR4","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041\u20132049. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.038","journal-title":"Ophthalmology"},{"key":"7555_CR5","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, Lai TYY, Haskova Z, Sakamoto T, Kotecha A, Schlottmann PG, Liu Y, Seres A, Retiere AC, Willis JR, Yoon YH, Balaton, Investigators C (2024) Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology 131:950\u2013960. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029","journal-title":"Ophthalmology"},{"key":"7555_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","volume":"9","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, Shimura M, Abreu F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann PG, Balaton, Investigators C (2025) Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. Ophthalmol Retina 9:848\u2013859. https:\/\/doi.org\/10.1016\/j.oret.2025.03.005","journal-title":"Ophthalmol Retina"},{"key":"7555_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.oret.2020.05.018","volume":"4","author":"AX Chen","year":"2020","unstructured":"Chen AX, Greenlee TE, Conti TF, Briskin IN, Singh RP (2020) Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents. Ophthalmol Retina 4:1158\u20131169. https:\/\/doi.org\/10.1016\/j.oret.2020.05.018","journal-title":"Ophthalmol Retina"},{"key":"7555_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/IAE.0000000000003349","volume":"42","author":"PU Dugel","year":"2022","unstructured":"Dugel PU, Jhaveri CD, Chakravarthy U, Wykoff CC, Singh RP, Hamilton R, Weissgerber G, Mulyukov Z, Holz FG (2022) Effect of retinal thickness variability on visual outcomes and fluid persistence in neovascular age-related macular degeneration: A Post Hoc Analysis of the HAWK and HARRIER Studies. Retina 42:511\u2013518. https:\/\/doi.org\/10.1097\/IAE.0000000000003349","journal-title":"Retina"},{"key":"7555_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"RN Evans","year":"2020","unstructured":"Evans RN, Reeves BC, Maguire MG, Martin DF, Muldrew A, Peto T, Rogers C, Chakravarthy U (2020) Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol 138:1043\u20131051. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3001","journal-title":"JAMA Ophthalmol"},{"key":"7555_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.oret.2024.10.015","volume":"9","author":"VS Sheth","year":"2025","unstructured":"Sheth VS, Holekamp NM, Khanani AM, Rachitskaya A, Blotner S, Gune S, Heinrich D, Maass KF, Chakravarthy U (2025) Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections. Ophthalmol Retina 9:330\u2013342. https:\/\/doi.org\/10.1016\/j.oret.2024.10.015","journal-title":"Ophthalmol Retina"},{"key":"7555_CR11","doi-asserted-by":"publisher","first-page":"100418","DOI":"10.1016\/j.xops.2023.100418","volume":"4","author":"D Nagasato","year":"2024","unstructured":"Nagasato D, Muraoka Y, Tanabe M, Nishigori N, Osaka R, Mitamura Y, Tabuchi H, Murakami T, Ooto S, Suzuma K, Tsujikawa A (2024) Foveal Thickness Fluctuations in Anti-VEGF Treatment for Central Retinal Vein Occlusion. Ophthalmol Sci 4:100418. https:\/\/doi.org\/10.1016\/j.xops.2023.100418","journal-title":"Ophthalmol Sci"},{"key":"7555_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrm2639","volume":"10","author":"HG Augustin","year":"2009","unstructured":"Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165\u2013177. https:\/\/doi.org\/10.1038\/nrm2639","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7555_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, Schlottmann PG, Paris LP, Westenskow PD, Quezada-Ruiz C (2021) The angiopoietin\/tie pathway in retinal vascular diseases: a review. Retina 41:1\u201319. https:\/\/doi.org\/10.1097\/IAE.0000000000003003","journal-title":"Retina"},{"key":"7555_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8:1265\u20131288. https:\/\/doi.org\/10.15252\/emmm.201505889","journal-title":"EMBO Mol Med"},{"key":"7555_CR15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M (2021) Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond) 35:1305\u20131316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x","journal-title":"Eye (Lond)"},{"key":"7555_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","volume":"34","author":"AH Ross","year":"2020","unstructured":"Ross AH, Downey L, Devonport H, Gale RP, Kotagiri A, Mahmood S, Mehta H, Narendran N, Patel PJ, Parmar N, Jain N (2020) Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye (Lond) 34:1825\u20131834. https:\/\/doi.org\/10.1038\/s41433-019-0747-x","journal-title":"Eye (Lond)"},{"key":"7555_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489\u20131506. https:\/\/doi.org\/10.1097\/IAE.0000000000000627","journal-title":"Retina"},{"key":"7555_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-07091-2","author":"A Kilani","year":"2026","unstructured":"Kilani A, Vogt D, Moysidi V, Assaf A, Wolf A, Vounotrypidis E (2026) VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-025-07091-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7555_CR19","doi-asserted-by":"publisher","unstructured":"Fischer S, Hoffmann L, Hatz K (2026) Long-term disease control with anti-VEGF treat-and-extend treatment in macular edema due to retinal vein occlusion. BMC Ophthalmol 26. https:\/\/doi.org\/10.1186\/s12886-026-04808-7","DOI":"10.1186\/s12886-026-04808-7"},{"key":"7555_CR20","doi-asserted-by":"publisher","unstructured":"Arai Y, Takahashi H, Inoda S, Sakamoto S, Tan X, Kawashima H, Yanagi Y (2023) Efficacy of a modified treat-and-extend aflibercept regimen for macular oedema in eyes with central retinal vein occlusion: 2-year prospective study. J Clin Med 12. https:\/\/doi.org\/10.3390\/jcm12155089","DOI":"10.3390\/jcm12155089"},{"key":"7555_CR21","doi-asserted-by":"publisher","unstructured":"Hafner M, Herold TR, Kufner A, Asani B, Anschutz A, Eckardt F, Priglinger SG, Schiefelbein J (2025) Switching to faricimab in therapy-resistant macular edema due to retinal vein occlusion: initial real-world efficacy outcomes. J Clin Med 14. https:\/\/doi.org\/10.3390\/jcm14072454","DOI":"10.3390\/jcm14072454"},{"key":"7555_CR22","doi-asserted-by":"publisher","unstructured":"Hafner M, Herold TR, Kufner A, Eckardt F, Asani B, Priglinger SG, Schiefelbein J (2025) Extended real-world efficacy of faricimab in therapy-resistant macular edema due to retinal vein occlusion: 9-month follow-up results. J Clin Med 14. https:\/\/doi.org\/10.3390\/jcm14207197","DOI":"10.3390\/jcm14207197"},{"key":"7555_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40942-025-00703-3","volume":"11","author":"T Hirakata","year":"2025","unstructured":"Hirakata T, Toride A, Ashikaga K, Nakagawa T, Hara F, Nochi Y, Yamamoto S, Hiratsuka Y, Nakao S (2025) Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion. Int J Retina Vitreous 11:79. https:\/\/doi.org\/10.1186\/s40942-025-00703-3","journal-title":"Int J Retina Vitreous"},{"key":"7555_CR24","doi-asserted-by":"publisher","unstructured":"Kilani A, Assaf A, Vogt D, Vounotrypidis E, Parlak M, Jochem C, Wolf A (2026) Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study. BMC Ophthalmol 26. https:\/\/doi.org\/10.1186\/s12886-026-04695-y","DOI":"10.1186\/s12886-026-04695-y"},{"key":"7555_CR25","doi-asserted-by":"publisher","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, Investigators C (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1124\u20131133 e1121 https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.022","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"7555_CR26","doi-asserted-by":"publisher","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Investigators B (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1102\u20131112 e1101 https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.021","DOI":"10.1016\/j.ophtha.2010.02.021"},{"key":"7555_CR27","doi-asserted-by":"publisher","unstructured":"Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155: 429\u2013437 e427 https:\/\/doi.org\/10.1016\/j.ajo.2012.09.026","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"7555_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ, Chang A, Gibson K, Joussen AM, Kim JE, Lee J, Margaron P, Saffar I, Wong D, Wykoff C, Sadda S (2025) Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol 263:1239\u20131247. https:\/\/doi.org\/10.1007\/s00417-024-06695-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7555_CR29","doi-asserted-by":"publisher","first-page":"1646806","DOI":"10.3389\/fphar.2025.1646806","volume":"16","author":"Y Jing","year":"2025","unstructured":"Jing Y, Li D (2025) Faricimab for retinal vein occlusion: a review of current evidence and future perspectives. Front Pharmacol 16:1646806. https:\/\/doi.org\/10.3389\/fphar.2025.1646806","journal-title":"Front Pharmacol"},{"key":"7555_CR30","doi-asserted-by":"publisher","first-page":"5552824","DOI":"10.1155\/2021\/5552824","volume":"2021","author":"M Li","year":"2021","unstructured":"Li M, Li J, Chen K, Wang J, Sheng M, Li B (2021) Association between Inflammatory Factors in the Aqueous Humor and Hyperreflective Foci in Patients with Intractable Macular Edema Treated with Antivascular Endothelial Growth Factor. Dis Markers 2021:5552824. https:\/\/doi.org\/10.1155\/2021\/5552824","journal-title":"Dis Markers"},{"key":"7555_CR31","doi-asserted-by":"publisher","unstructured":"Munk MR, Ceklic L, Stillenmunkes R, Chaudhary V, Waheed N, Chhablani J, de Smet MD, Tillmann A (2024) integrated assessment of OCT, multimodal imaging, and cytokine markers for predicting treatment responses in retinal vein occlusion associated macular edema: a comparative review of anti-VEGF and steroid therapies. Diagnostics (Basel) 14. https:\/\/doi.org\/10.3390\/diagnostics14171983","DOI":"10.3390\/diagnostics14171983"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07555-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:07:31Z","timestamp":1791907651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07555-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":31,"alternative-id":["7555"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07555-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the University of Ulm (Ethikkommission der Universit\u00e4t Ulm; application number 387\/24; decision date: January 13, 2025) and conducted in accordance with the Declaration of Helsinki. All study participants received an informed consent form (version no. 2, dated January 07, 2025) approved by the University of Ulm\u2019s Ethics Committee prior to participating in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"German Clinical Trials Register (DRKS) registration ID: DRKS00036984.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used the free web-based versions of DeepL (DeepL SE, Cologne, Germany) and ChatGPT (OpenAI, San Francisco, USA) to improve the clarity and readability of the text. The tools were applied with caution, and all resulting content was thoroughly reviewed, verified, and edited by the authors. The authors take full responsibility for the final content of the manuscript.","order":5,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}